Tony Berberabe, MPH | Authors

March 25, 2021

In addition to promising effects on tumor progression risk, apatinib added to doxorubicin for ovarian cancer in certain settings increased overall response rate versus single-agent doxorubicin.

March 20, 2021

A dostarlimab triplet combination showed promise in a phase 2 study for treatment of patients with platinum-resistant ovarian cancer, according to a presentation at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer.

February 14, 2021

In patients with cisplatin-ineligible, locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors, enfortumab vedotin induced the highest response rates seen with any regimen in this setting.

January 29, 2021

A Japanese study supports the use of nab-paclitaxel for previously treated non–small cell lung cancer based on noninferiority end points being met.

January 19, 2021

No significant benefits to progression-free survival were noted with the axitinib-plus-octreotide combination for the treatment of patients with advanced G1-2 extra-pancreatic neuroendocrine tumors.

December 10, 2020

After breast-conserving surgery and adjuvant endocrine therapy, whole breast irradiation can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years.

December 06, 2020

The enriched chimeric antigen receptor T-cell therapy improved responses and prolonged duration of response in patients with relapsed/refractory multiple myeloma.

June 07, 2020

The CAR T-cell therapy continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.